Ogawa Y, Chung Y S, Nakata B, Takatsuka S, Maeda K, Sawada T, Kato Y, Yoshikawa K, Sowa M
First Dept. of Surgery, Osaka City University Medical School.
Gan To Kagaku Ryoho. 1995 Apr;22 Suppl 1:66-70.
The clinical significance of AgNOR and microvessel quantitation as prognostic indicators in Stage I breast cancer were examined. This study included 99 patients with Stage I breast cancer, with a median follow-up period of 119 months. AgNOR was stained by Crocker's method and microvessels were identified by immunohistochemical staining for Factor VIII-related antigen in formalin-fixed, paraffin-embedded primary tumors. AgNOR score related with tumor size. Microvessel count was related to estrogen receptor status. When patients were classified into two groups by the mean AgNOR score, higher scores had a tendency to be correlated with shorter overall survival. And when classified by microvessel count, higher counts were significantly associated with shorter overall, survival (p < 0.01). The microvessel count might be a useful predictor and the AgNOR score could be used to corroborate predictions for identifying patients at high risk for relapse and death in Stage I breast cancer.
研究了核仁组成区嗜银蛋白(AgNOR)和微血管定量作为Ⅰ期乳腺癌预后指标的临床意义。本研究纳入了99例Ⅰ期乳腺癌患者,中位随访期为119个月。采用克罗克氏法对AgNOR进行染色,并通过免疫组织化学染色检测福尔马林固定、石蜡包埋的原发性肿瘤中Ⅷ因子相关抗原以识别微血管。AgNOR评分与肿瘤大小相关。微血管计数与雌激素受体状态相关。当根据平均AgNOR评分将患者分为两组时,较高的评分往往与较短的总生存期相关。而根据微血管计数进行分类时,较高的计数与较短的总生存期显著相关(p<0.01)。微血管计数可能是一个有用的预测指标,AgNOR评分可用于佐证对Ⅰ期乳腺癌复发和死亡高危患者的预测。